<ul>
<li>布里斯托尔 - 迈尔斯斯奎布公司的大手笔收购：在两笔生物科技交易中投资 181 亿美元</li>
</ul>
<p>Xenon Pharmaceuticals Inc.（纳斯达克：XENE - 免费报告）- Cantor Fitzgerald 的研究分析师在 8 月 12 日（星期二）发布的报告中下调了对 Xenon Pharmaceuticals 2025 财年每股收益（EPS）的预期。Cantor Fitzgerald 的分析师 J. Schimmer 现在预测该生物制药公司 2025 财年每股收益为（$3.85），低于之前的预期（$3.43）。市场普遍预期 Xenon Pharmaceuticals 当前全年的每股收益为（$3.10）。Cantor Fitzgerald 还对 Xenon Pharmaceuticals 2026 财年的每股收益预期为（$4.08）。</p>
<p>Xenon Pharmaceuticals（纳斯达克：XENE - 获取免费报告）最近在 8 月 11 日（星期一）发布了其财报。该生物制药公司报告本季度每股收益为（$1.07），低于市场普遍预期的（$1.03），差额为（$0.04）。在去年同期，该公司每股收益为（$0.75）。</p>
<p>获取 <strong>Xenon Pharmaceuticals</strong> 的提醒：</p>
<p>其他几家研究公司也最近对 XENE 发表了看法。Needham &amp; Company LLC 将 Xenon Pharmaceuticals 的目标价从$60.00 下调至$55.00，并在 5 月 13 日（星期二）的报告中给予该公司 “买入” 评级。William Blair 在 5 月 5 日（星期一）的报告中重申了对 Xenon Pharmaceuticals 股票的 “跑赢大盘” 评级。Wells Fargo &amp; Company 将 Xenon Pharmaceuticals 的目标价从$50.00 下调至$47.00，并在 5 月 13 日（星期二）的报告中给予该公司 “增持” 评级。加拿大皇家银行在周二的研究报告中将 Xenon Pharmaceuticals 的目标价从$57.00 下调至$55.00，并给予该公司 “跑赢大盘” 评级。最后，华尔街 Zen 在 5 月 21 日（星期三）的研究报告中将 Xenon Pharmaceuticals 的评级从 “持有” 下调至 “卖出”。一位研究分析师对该股票给予了 “卖出” 评级，而十一位分析师给予了 “买入” 评级。根据 MarketBeat 的数据，Xenon Pharmaceuticals 目前的平均评级为 “适度买入”，共识目标价为$53.20。</p>
<p><strong>获取我们关于 Xenon Pharmaceuticals 的最新报告</strong></p>
<h2>Xenon Pharmaceuticals 股票表现</h2>
<p>纳斯达克 XENE 周四开盘价为$37.67。Xenon Pharmaceuticals 的 52 周低点为$26.74，52 周高点为$46.00。该股票的 50 日简单移动平均为$32.31，200 日简单移动平均为$34.09。该股票的市值为 29 亿美元，市盈率为-10.61，贝塔值为 1.16。</p>
<h2>机构资金流入和流出</h2>
<p>一些机构投资者和对冲基金最近增加或减少了在 XENE 的持股。Geode Capital Management LLC 在第四季度将其在 Xenon Pharmaceuticals 的持股增加了 1.0%。Geode Capital Management LLC 目前拥有 69,529 股该生物制药公司的股票，价值$2,726,000，此前在上个季度又购买了 720 股。Raymond James Financial Inc.在第四季度购买了 Xenon Pharmaceuticals 的新头寸，价值约$797,000。Barclays PLC 在第四季度将其在 Xenon Pharmaceuticals 的持股增加了 20.9%。Barclays PLC 目前拥有 18,127 股该生物制药公司的股票，价值$711,000，此前在上个季度又购买了 3,134 股。XTX Topco Ltd 在第四季度购买了 Xenon Pharmaceuticals 的新头寸，价值约$316,000。最后，Walleye Capital LLC 在第四季度将其在 Xenon Pharmaceuticals 的持股增加了 111.5%。Walleye Capital LLC 目前拥有 221,982 股该生物制药公司的股票，价值$8,702,000，此前在上个季度又购买了 117,022 股。机构投资者持有该公司 95.45% 的股票。</p>
<h2>Xenon Pharmaceuticals 公司简介</h2>
<p>（获取免费报告）</p>
<p>Xenon Pharmaceuticals Inc 是一家专注于神经科学的生物制药公司，致力于开发治疗加拿大神经系统疾病患者的疗法。其临床开发管线包括 XEN1101，这是一种新型且有效的 Kv7 钾通道开放剂，目前正在进行针对癫痫和其他神经系统疾病的三期临床试验。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票，而不是 Xenon Pharmaceuticals</li>
<li>REIT 股票 - 今天值得添加到您投资组合中的最佳 REIT 股票</li>
<li>数据中心为这三只核能股票创造了看涨案例</li>
<li>什么是日经 225 指数？</li>
<li>特斯拉的旗形图刚刚破裂：这对股票意味着什么</li>
<li>5 只值得考虑的高评级分红股票</li>
<li>3 家公司将从特朗普的半导体关税中获利</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9WEVORQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9WEVORQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审查。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 Xenon Pharmaceuticals 吗？</h2>
<p>在你考虑 Xenon Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Xenon Pharmaceuticals 并不在名单上。</p>
<p>虽然 Xenon Pharmaceuticals 目前在分析师中获得了 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

Xenon制药

<p>Cantor Fitzgerald 将 Xenon Pharmaceuticals (NASDAQ:XENE) 的 2025 财年每股收益（EPS）预估从（$3.43）下调至（$3.85），而市场共识预估为（$3.10）。该公司还预计 2026 财年的每股收益为（$4.08）。Xenon 报告的季度每股收益为（$1.07），未能达到预期。多位分析师已调整其目标价，平均评级为 “适度买入”，共识目标价为 $53.20。该股票开盘价为 $37.67，市值为 29 亿美元，机构持股比例为 95.45%</p>

<ul>
<li>Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals</li>
</ul>
<div class="lb-trans"><ul>
<li>布里斯托尔 - 迈尔斯斯奎布公司的大手笔收购：在两笔生物科技交易中投资 181 亿美元</li>
</ul>
</div><p>Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) - Research analysts at Cantor Fitzgerald cut their FY2025 earnings per share (EPS) estimates for shares of Xenon Pharmaceuticals in a report released on Tuesday, August 12th. Cantor Fitzgerald analyst J. Schimmer now forecasts that the biopharmaceutical company will earn ($3.85) per share for the year, down from their previous estimate of ($3.43). The consensus estimate for Xenon Pharmaceuticals' current full-year earnings is ($3.10) per share. Cantor Fitzgerald also issued estimates for Xenon Pharmaceuticals' FY2026 earnings at ($4.08) EPS.</p>
<div class="lb-trans"><p>Xenon Pharmaceuticals Inc.（纳斯达克：XENE - 免费报告）- Cantor Fitzgerald 的研究分析师在 8 月 12 日（星期二）发布的报告中下调了对 Xenon Pharmaceuticals 2025 财年每股收益（EPS）的预期。Cantor Fitzgerald 的分析师 J. Schimmer 现在预测该生物制药公司 2025 财年每股收益为（$3.85），低于之前的预期（$3.43）。市场普遍预期 Xenon Pharmaceuticals 当前全年的每股收益为（$3.10）。Cantor Fitzgerald 还对 Xenon Pharmaceuticals 2026 财年的每股收益预期为（$4.08）。</p>
</div><p>Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last issued its earnings results on Monday, August 11th. The biopharmaceutical company reported ($1.07) earnings per share for the quarter, missing the consensus estimate of ($1.03) by ($0.04). During the same quarter in the prior year, the firm posted ($0.75) earnings per share.</p>
<div class="lb-trans"><p>Xenon Pharmaceuticals（纳斯达克：XENE - 获取免费报告）最近在 8 月 11 日（星期一）发布了其财报。该生物制药公司报告本季度每股收益为（$1.07），低于市场普遍预期的（$1.03），差额为（$0.04）。在去年同期，该公司每股收益为（$0.75）。</p>
</div><p>Get <strong>Xenon Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Xenon Pharmaceuticals</strong> 的提醒：</p>
</div><p>Several other research firms have also recently weighed in on XENE. Needham &amp; Company LLC dropped their price objective on Xenon Pharmaceuticals from $60.00 to $55.00 and set a &#34;buy&#34; rating for the company in a report on Tuesday, May 13th. William Blair reiterated an &#34;outperform&#34; rating on shares of Xenon Pharmaceuticals in a report on Monday, May 5th. Wells Fargo &amp; Company dropped their price objective on Xenon Pharmaceuticals from $50.00 to $47.00 and set an &#34;overweight&#34; rating for the company in a report on Tuesday, May 13th. Royal Bank Of Canada lowered their target price on Xenon Pharmaceuticals from $57.00 to $55.00 and set an &#34;outperform&#34; rating for the company in a research note on Tuesday. Finally, Wall Street Zen cut Xenon Pharmaceuticals from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research note on Wednesday, May 21st. One research analyst has rated the stock with a sell rating and eleven have given a buy rating to the stock. Based on data from MarketBeat, Xenon Pharmaceuticals currently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $53.20.</p>
<div class="lb-trans"><p>其他几家研究公司也最近对 XENE 发表了看法。Needham &amp; Company LLC 将 Xenon Pharmaceuticals 的目标价从$60.00 下调至$55.00，并在 5 月 13 日（星期二）的报告中给予该公司 “买入” 评级。William Blair 在 5 月 5 日（星期一）的报告中重申了对 Xenon Pharmaceuticals 股票的 “跑赢大盘” 评级。Wells Fargo &amp; Company 将 Xenon Pharmaceuticals 的目标价从$50.00 下调至$47.00，并在 5 月 13 日（星期二）的报告中给予该公司 “增持” 评级。加拿大皇家银行在周二的研究报告中将 Xenon Pharmaceuticals 的目标价从$57.00 下调至$55.00，并给予该公司 “跑赢大盘” 评级。最后，华尔街 Zen 在 5 月 21 日（星期三）的研究报告中将 Xenon Pharmaceuticals 的评级从 “持有” 下调至 “卖出”。一位研究分析师对该股票给予了 “卖出” 评级，而十一位分析师给予了 “买入” 评级。根据 MarketBeat 的数据，Xenon Pharmaceuticals 目前的平均评级为 “适度买入”，共识目标价为$53.20。</p>
</div><p><strong>Get Our Latest Report on Xenon Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 Xenon Pharmaceuticals 的最新报告</strong></p>
</div><h2>Xenon Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>Xenon Pharmaceuticals 股票表现</h2>
</div><p>NASDAQ XENE opened at $37.67 on Thursday. Xenon Pharmaceuticals has a fifty-two week low of $26.74 and a fifty-two week high of $46.00. The stock has a 50 day simple moving average of $32.31 and a two-hundred day simple moving average of $34.09. The stock has a market cap of $2.90 billion, a P/E ratio of -10.61 and a beta of 1.16.</p>
<div class="lb-trans"><p>纳斯达克 XENE 周四开盘价为$37.67。Xenon Pharmaceuticals 的 52 周低点为$26.74，52 周高点为$46.00。该股票的 50 日简单移动平均为$32.31，200 日简单移动平均为$34.09。该股票的市值为 29 亿美元，市盈率为-10.61，贝塔值为 1.16。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>A number of institutional investors and hedge funds have recently added to or reduced their stakes in XENE. Geode Capital Management LLC increased its position in Xenon Pharmaceuticals by 1.0% during the 4th quarter. Geode Capital Management LLC now owns 69,529 shares of the biopharmaceutical company's stock valued at $2,726,000 after buying an additional 720 shares in the last quarter. Raymond James Financial Inc. bought a new position in Xenon Pharmaceuticals during the 4th quarter valued at approximately $797,000. Barclays PLC increased its position in Xenon Pharmaceuticals by 20.9% during the 4th quarter. Barclays PLC now owns 18,127 shares of the biopharmaceutical company's stock valued at $711,000 after buying an additional 3,134 shares in the last quarter. XTX Topco Ltd bought a new position in Xenon Pharmaceuticals during the 4th quarter valued at approximately $316,000. Finally, Walleye Capital LLC increased its position in Xenon Pharmaceuticals by 111.5% during the 4th quarter. Walleye Capital LLC now owns 221,982 shares of the biopharmaceutical company's stock valued at $8,702,000 after buying an additional 117,022 shares in the last quarter. Institutional investors own 95.45% of the company's stock.</p>
<div class="lb-trans"><p>一些机构投资者和对冲基金最近增加或减少了在 XENE 的持股。Geode Capital Management LLC 在第四季度将其在 Xenon Pharmaceuticals 的持股增加了 1.0%。Geode Capital Management LLC 目前拥有 69,529 股该生物制药公司的股票，价值$2,726,000，此前在上个季度又购买了 720 股。Raymond James Financial Inc.在第四季度购买了 Xenon Pharmaceuticals 的新头寸，价值约$797,000。Barclays PLC 在第四季度将其在 Xenon Pharmaceuticals 的持股增加了 20.9%。Barclays PLC 目前拥有 18,127 股该生物制药公司的股票，价值$711,000，此前在上个季度又购买了 3,134 股。XTX Topco Ltd 在第四季度购买了 Xenon Pharmaceuticals 的新头寸，价值约$316,000。最后，Walleye Capital LLC 在第四季度将其在 Xenon Pharmaceuticals 的持股增加了 111.5%。Walleye Capital LLC 目前拥有 221,982 股该生物制药公司的股票，价值$8,702,000，此前在上个季度又购买了 117,022 股。机构投资者持有该公司 95.45% 的股票。</p>
</div><h2>Xenon Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Xenon Pharmaceuticals 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.</p>
<div class="lb-trans"><p>Xenon Pharmaceuticals Inc 是一家专注于神经科学的生物制药公司，致力于开发治疗加拿大神经系统疾病患者的疗法。其临床开发管线包括 XEN1101，这是一种新型且有效的 Kv7 钾通道开放剂，目前正在进行针对癫痫和其他神经系统疾病的三期临床试验。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Xenon Pharmaceuticals</li>
<li>REIT Stocks - Best REIT Stocks to Add to Your Portfolio Today</li>
<li>Data Centers Create a Bull Case for These Nuclear 3 Stocks</li>
<li>What is the Nikkei 225 index?</li>
<li>Tesla’s Pennant Just Snapped: Here’s What It Means for the Stock</li>
<li>5 Top Rated Dividend Stocks to Consider</li>
<li>3 Companies That Will Profit From Trump's Semiconductor Tariffs</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Xenon Pharmaceuticals</li>
<li>REIT 股票 - 今天值得添加到您投资组合中的最佳 REIT 股票</li>
<li>数据中心为这三只核能股票创造了看涨案例</li>
<li>什么是日经 225 指数？</li>
<li>特斯拉的旗形图刚刚破裂：这对股票意味着什么</li>
<li>5 只值得考虑的高评级分红股票</li>
<li>3 家公司将从特朗普的半导体关税中获利</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9WEVORQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=XENE"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审查。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Xenon Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 Xenon Pharmaceuticals 吗？</h2>
</div><p>Before you consider Xenon Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Xenon Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xenon Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Xenon Pharmaceuticals 并不在名单上。</p>
</div><p>While Xenon Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Xenon Pharmaceuticals 目前在分析师中获得了 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Cantor Fitzgerald 下调了 Xenon Pharma 2025 财年的每股收益预期